Final results of phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL+BV; SOLA) in metastatic colorectal cancer (mCRC).
Kentaro Yamazaki
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Tomohiro Nishina
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Takeshi Kato
No relevant relationships to disclose
Takayuki Yoshino
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult
Yoshinori Miyata
No relevant relationships to disclose
Taito Esaki
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Toshikazu Moriwaki
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Narikazu Boku
Honoraria - Taiho Pharmaceutical; Yakult
Research Funding - Taiho Pharmaceutical
Ichinosuke Hyodo
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Yakult